Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations

Journal of Clinical Neuroscience

Volumn 21, Issue 11, 2014, Pages 1857-1865

  Broadley, Simon A ^a,b   Barnett, Michael H ^c   Boggild, Mike ^d   Brew, Bruce J ^e   Butzkueven, Helmut ^f,r   Heard, Robert ^g   Hodgkinson, Suzanne ^h   Kermode, Allan G ⁱ   Lechner Scott, Jeannette ^j   Macdonell, Richard A L ^k   Marriott, Mark ^f   Mason, Deborah F ^l   Parratt, John ^c   Reddel, Stephen W ^c   Shaw, Cameron P ^m   Slee, Mark ⁿ   Spies, Judith ^c   Taylor, Bruce V ^o   Carroll, William M ⁱ   Kilpatrick, Trevor J ^o   King, John ^f   McCombe, Pamela A ^p   Pollard, John D ^c   Willoughby, Ernest ^q   more..

^a GRIFFITH UNIVERSITY   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d TOWNSVILLE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g University of Sydney   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j UNIVERSITY OF NEWCASTLE   (Australia)

^k AUSTIN HEALTH   (Australia)

^l CHRISTCHURCH HOSPITAL   (New Zealand)

^m DEAKIN UNIVERSITY   (Australia)

ⁿ FLINDERS UNIVERSITY   (Australia)

^o UNIVERSITY OF TASMANIA   (Australia)

^p UNIVERSITY OF QUEENSLAND   (Australia)

^q AUCKLAND CITY HOSPITAL   (New Zealand)

^r MONASH UNIVERSITY   (Australia)

more..

Author keywords

Evidence based medicine; Guideline; Multiple sclerosis; Review; Treatment

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RITUXIMAB; TERIFLUNOMIDE; BETA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANTIBODY SCREENING; ANXIETY DISORDER; AUSTRALIA; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNE THYROIDITIS; BLOOD EXAMINATION; BRADYCARDIA; BREAST FEEDING; COOLING; DEBRIDEMENT; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FETUS DISEASE; FETUS MALFORMATION; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEART PALPITATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LIVER FUNCTION TEST; LOW BIRTH WEIGHT; LYMPHOCYTOPENIA; MACULAR EDEMA; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NECROSIS; NEUTROPENIA; NEW ZEALAND; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PATIENT EDUCATION; PATIENT MONITORING; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PREGNANCY; PREMATURITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; SPONTANEOUS ABORTION; THORAX PAIN; THROAT TIGHTNESS; URTICARIA; VISUAL SYSTEM EXAMINATION; ADULT; CONSENSUS DEVELOPMENT; DISEASE COURSE; DISEASE MANAGEMENT; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXPERIMENTAL THERAPY; FEMALE; FORECASTING; IMMUNOLOGY; ISOLATION AND PURIFICATION; JC VIRUS; LACTATION; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; PATHOLOGY; PRACTICE GUIDELINE; PREGNANCY COMPLICATIONS; SERODIAGNOSIS; TREATMENT OUTCOME; TRENDS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AUSTRALIA; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; FORECASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; JC VIRUS; LACTATION; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; NEW ZEALAND; PREGNANCY; PREGNANCY COMPLICATIONS; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 84908360357     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.01.017     Document Type: Review

References (122)

1. I. Bosca, F. Coret, and C. Valero Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon Mult Scler 14 2008 636 639
2. M.P. Sormani, J. Rio, and M. Tintorè Scoring treatment response in patients with relapsing multiple sclerosis Mult Scler 19 2013 605 612
3. J. Rio, M. Comabella, and X. Montalban Predicting responders to therapies for multiple sclerosis Nat Rev Neurol 5 2009 553 560
4. J. Rio, A. Rovira, and M. Tintorè Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients Mult Scler 14 2008 479 484
5. E. Havrdova, S. Galetta, and D. Stefoski Freedom from disease activity in multiple sclerosis Neurology 74 2010 S3 S7
6. R.A. Rudick, and C.H. Polman Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis Lancet Neurol 8 2009 545 559
7. J. Rio, M. Tintoré, and J. Sastre-Garriga Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response Eur J Neurol 19 2012 899 904
8. M.S. Freedman, D. Selchen, and D.L. Arnold Treatment optimization in MS: Canadian MS Working Group updated recommendations Can J Neurol Sci 40 2013 307 323
9. K.P. Johnson, B.R. Brooks, and J.A. Cohen Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
10. D.H. Miller, and J.A. Frank Magnetic resonance imaging techniques to monitor short term evolution of multiple sclerosis and to use in preliminary trials J Neurol Neurosurg Psychiatry 64 1998 S44 S46
11. P.K. Coyle Switching algorithms: from one immunomodulatory agent to another J Neurol 255 2008 44 50
12. E. Portaccio, V. Zipoli, and G. Siracusa Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients Eur Neurol 61 2009 177 182
13. V.G. Jokubaitis, T. Spelman, and J. Lechner-Scott The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform PLoS One 8 2013 e59694
14. N. Grytten, J.H. Aarseth, and K. Espeset Stoppers and non-starters of disease-modifying treatment in multiple sclerosis Acta Neurol Scand 127 2013 133 140
15. A. Gajofatto, P. Bacchetti, and B. Grimes Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Mult Scler 15 2009 50 58
16. A. Carra, P. Onaha, and G. Luetic Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina Eur J Neurol 15 2008 386 393
17. J.E. Meca-Lallana, J.J. Balseiro, and F. Lacruz Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study J Neurol Sci 315 2012 123 128
18. M. Capobianco, A. Rizzo, and S. Malucchi Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients Neurol Sci 29 2008 S227 S229
19. H.L. Zwibel Copolymer-1 Treatment Study Principal I. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients Acta Neurol Scand 113 2006 378 386
20. S. Belachew, R. Phan-Ba, and E. Bartholomé Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis Eur J Neurol 18 2011 240 245
21. T. Castillo-Trivino, E.M. Mowry, and A. Gajofatto Switching multiple sclerosis patients with breakthrough disease to second-line therapy PLoS One 6 2011 e16664
22. R. Lanzillo, S. Bonavita, and M. Quarantelli Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice Neurol Sci 34 2013 521 528
23. L. Prosperini, C. Giannì, and L. Leonardi Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis Mult Scler 18 2012 64 71
24. J. Havla, L.A. Gerdes, and I. Meinl De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate J Neurol 258 2011 1665 1669
25. J. Havla, B. Tackenberg, and K. Hellwig Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis J Neurol 260 2013 1382 1387
26. F. Rinaldi, D. Seppi, and M. Calabrese Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings Mult Scler 18 2012 1640 1643
27. A.P. Sempere, P. Martin-Medina, and L. Berenguer-Ruiz Switching from natalizumab to fingolimod: an observational study Acta Neurol Scand 128 2013 e6 e10
28. S. Marousi, M. Travasarou, and C.E. Karageorgiou Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS Neurology 79 2012 2160
29. S. Gheuens, D.R. Smith, and X. Wang Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS Neurology 78 2012 1390 1393
30. V. Martinelli, B. Colombo, and G. Dalla Costa Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning Mult Scler 2013 [Epub ahead of print]
31. M.M. Vellinga, J.A. Castelijns, and F. Barkhof Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients Neurology 70 2008 1150 1151
32. S. Jander, B. Turowski, and B.C. Kieseier Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod Mult Scler 18 2012 1650 1652
33. A. Kerbrat, E. Le Page, and E. Leray Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients J Neurol Sci 308 2011 98 102
34. E. Lu, B.W. Wang, and C. Guimond Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review Neurology 79 2012 1130 1135
35. Biogen Idec Australia Pty Ltd., Product Information - Avonex. Australia: TGA; 28 Jul 2009.
36. Biogen Idec NZ Ltd., Data Sheet - Avonex. Auckland, NZ: Medsafe; 22 Aug 2012.
37. Merck Serono Australia Pty Ltd., Product Information - Rebif. Australia: TGA; 15 Aug 2012.
38. Bayer Australia Limited. Product Information - Betaferon. Australia: TGA; 5 Nov 2010.
39. Bayer New Zealand Limited. Data Sheet - Betaferon. Auckland, NZ: Medsafe; 9 Aug 2010.
40. CSL Biotherapies (NZ) Limited. Data Sheet - Copaxone. Auckland, NZ: Medsafe; 1 Feb 2012.
41. CSL Limited. Product Information - Copaxone. Australia: TGA; 10 Apr 2012.
42. Biogen Idec Australia Pty Ltd., Product Information - Tysabri. Australia: TGA; 26 Nov 2010.
43. Biogen Idec NZ Ltd., Data Sheet - Tysabri. Auckland, NZ: Medsafe; 21 Nov 2012.
44. Novartis New Zealand Limited. Data Sheet - Gilenya. Auckland, NZ: Medsafe; 3 Sep 2012.
45. Novartis Pharmaceuticals Australia Pty Limited. Product Information - Gilenya. Australia: TGA; 11 Oct 2012.
46. Sanofi-Aventis Australia Pty Ltd., Product Information - Aubagio. Australia: TGA; 14 Nov 2012.
47. Biogen Idec Australia Pty Ltd., Product Information - Tecfidera. Australia: TGA; 21 Aug 2013.
48. Genzyme Corporation. Prescibing Information - Campath. US: FDA; 19 Sep 2007.
49. B.J. Cleary, and B. Källén Early pregnancy azathioprine use and pregnancy outcomes Birth Defects Res A Clin Mol Teratol 85 2009 647 654
50. L.H. Goldstein, G. Dolinsky, and R. Greenberg Pregnancy outcome of women exposed to azathioprine during pregnancy Birth Defects Res A Clin Mol Teratol 79 2007 696 701
51. V. Langagergaard, L. Pedersen, and M. Gislum Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study Aliment Pharmacol Ther 25 2007 73 81
52. M.E. Clowse, L. Magder, and M. Petri Cyclophosphamide for lupus during pregnancy Lupus 14 2005 593 597
53. M. Férnandez, R. Andrade, and G.S. Alarcon Cyclophosphamide use and pregnancy in lupus Lupus 15 2006 59
54. J.A. Martinez Lopez, E. Loza, and L. Carmona Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding) Clin Exp Rheumatol 27 2009 678 684
55. M. De Santis, G. Straface, and A.F. Cavaliere The first case of mitoxantrone exposure in early pregnancy Neurotoxicology 28 2007 696 697
56. K. Hellwig, S. Schimrigk, and A. Chan A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis J Neurol Sci 307 2011 164 165
57. V.T. Armenti, J.S. Radomski, and M.J. Moritz Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl 2005 69 83
58. N.M. Sifontis, L.A. Coscia, and S. Constantinescu Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus Transplantation 82 2006 1698 1702
59. R. Boskovic, R. Wide, and J. Wolpin The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort Neurology 65 2005 807 811
60. F. Patti, T. Cavallaro, and S. Lo Fermo Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 255 2008 1250 1253
61. M. Sandberg-Wollheim, E. Alteri, and M.S. Moraga Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy Mult Scler 17 2011 423 430
62. M. Sandberg-Wollheim, D. Frank, and T.M. Goodwin Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis Neurology 65 2005 802 806
63. M.P. Amato, E. Portaccio, and A. Ghezzi Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis Neurology 75 2010 1794 1802
64. K. Hellwig, H. Agne, and R. Gold Interferon beta, birth weight and pregnancy in multiple sclerosis J Neurol 256 2009 830 831
65. E. Lu, L. Dahlgren, and A. Sadovnick Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs Mult Scler 18 2012 460 467
66. S. Tomczyk, and B. Sperling Postmarketing pregnancy outcomes in patients exposed to intramuscular interferon beta 1a 2013 ECTRIMS Lyon, France
67. S. Tomczyk, K. Wallaace, and S. Liu Pregnancy outcomes from the AVONEX® (interferon beta-1a) pregnancy exposure registry 2012 ECTRIMS Lyon, France
68. M. Giannini, E. Portaccio, and A. Ghezzi Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study BMC Neurol 12 2012 124
69. H.J. Salminen, H. Leggett, and M. Boggild Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes J Neurol 257 2010 2020 2023
70. L. Cristiano, S. Friend, and C. Bozic Evaluation of Pregnancy Outcomes from the TYSABRI® (Natalizumab) Pregnancy Exposure Registry 2013 AAN San Diego
71. K. Hellwig, A. Haghikia, and R. Gold Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment Mult Scler 17 2011 958 963
72. K. Hellwig, G. Koren, and H. Butzkueven Cumulative data on pregnancy outcomes after exposure to fingolimod 2013 ECTRIMS Copenhagen, Denmark
73. B. Kieseier, O. Stuve, and M. Benamor Updated pregnancy outcomes from the teriflunomide clinical development program: retrospective analysis of the teriflunomide clinical trial database 2013 ECTRIMS Copenhagen, Denmark
74. R.J. Gold, J.T. Phillips, and E. Havrdova Oral BG-12 (dimethyl fumarate) and pregnancy: preclinical studies and pregnancy outcomes reported during the clinical development programme 2013 ECTRIMS Copenhagen, Denmark
75. Genzyme Corporation Alemtuzumab advisory committee briefing document 2013 FDA
76. L. Ammon Avalos, C. Galindo, and D.K. Li A systematic review to calculate background miscarriage rates using life table analysis Birth Defects Res A Clin Mol Teratol 94 2012 417 423
77. A. Jalkanen, A. Alanen, and L. Airas Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland Mult Scler 16 2010 950 955
78. F.E. Munschauer 3rd, and R.P. Kinkel Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis Clin Ther 19 1997 883 893
79. G. Comi, D. Jeffery, and L. Kappos Placebo-controlled trial of oral laquinimod for multiple sclerosis N Engl J Med 366 2012 1000 1009
80. I. Casetta, G. Iuliano, and G. Filippini Azathioprine for multiple sclerosis Cochrane Database Syst Rev 2007 CD003982
81. P. O'Connor, J.S. Wolinsky, and C. Confavreux Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 365 2011 1293 1303
82. L.D. Jacobs, D.L. Cookfair, and R.A. Rudick Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 1996 285 294
83. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group Neurology 43 1993 655 661
84. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group Lancet 352 1998 1498 1504
85. L. Kappos, E.W. Radue, and P. O'Connor A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
86. R. Gold, L. Kappos, and D.L. Arnold Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 2012 1098 1107
87. R.J. Fox, D.H. Miller, and J.T. Phillips Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 367 2012 1087 1097
88. C.H. Polman, P.W. O'Connor, and E. Havrdova A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
89. J.A. Cohen, A.J. Coles, and D.L. Arnold Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet 380 2012 1819 1828
90. A.J. Coles, C.L. Twyman, and D.L. Arnold Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 380 2012 1829 1839
91. J. Reess, J. Haas, and K. Gabriel Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy Mult Scler 8 2002 15 18
92. J. Rio, C. Nos, and M.E. Marzo Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS Neurology 50 1998 1910 1912
93. E. Frohman, T. Phillips, and K. Kokel Disease-modifying therapy in multiple sclerosis: strategies for optimizing management Neurologist 8 2002 227 236
94. L. Jacobs, A.M. Salazar, and R. Herndon Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis Lancet 2 1986 1411 1413
95. D.W. Brandes, T. Callender, and E. Lathi A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events Curr Med Res Opin 25 2009 77 92
96. J.L. Jones, and A.J. Coles Campath-1H treatment of multiple sclerosis Neurodegener Dis 5 2008 27 31
97. E.F. Wheelock, and S.T. Toy Participation of lymphocytes in viral infections Adv Immunol 16 1973 123 184
98. M. Tanaka, K. Park, and K. Tanaka Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia Mult Scler 19 2013 1244 1245
99. P.A. Pizzo Management of fever in patients with cancer and treatment-induced neutropenia N Engl J Med 328 1993 1323 1332
100. H. Panitch, D.S. Goodin, and G. Francis Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial Neurology 59 2002 1496 1506
101. A. Langer-Gould, H.H. Moses, and T.J. Murray Strategies for managing the side effects of treatments for multiple sclerosis Neurology 63 2004 S35 S41
102. K.R. Carson, D. Focosi, and E.O. Major Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project Lancet Oncol 10 2009 816 824
103. U. Ermis, J. Weis, and J.B. Schulz PML in a patient treated with fumaric acid N Engl J Med 368 2013 1657 1658
104. B.W. van Oosten, J. Killestein, and F. Barkhof PML in a patient treated with dimethyl fumarate from a compounding pharmacy N Engl J Med 368 2013 1658 1659
105. DA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). FDA; 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm [accessed 1 Nov 2013, 2013].
106. Biogen Idec. Tysabri® (natalizumab) safety update: 23 August 2013.
107. B.J. Brew, N.W. Davies, and P. Cinque Progressive multifocal leukoencephalopathy and other forms of JC virus disease Nat Rev Neurol 6 2010 667 679
108. A. Boster, S. Hreha, and J.R. Berger Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study Arch Neurol 66 2009 593 599
109. M.A. Sahraian, E.W. Radue, and A. Eshaghi Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis Eur J Neurol 19 2012 1060 1069
110. D.B. Clifford, A. De Luca, and D.M. Simpson Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 2010 438 446
111. I.L. Tan, J.C. McArthur, and D.B. Clifford Immune reconstitution inflammatory syndrome in natalizumab-associated PML Neurology 77 2011 1061 1067
112. P. O'Connor, G. Comi, and X. Montalban Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study Neurology 72 2009 73 79
113. J.A. Cohen, F. Barkhof, and G. Comi Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
114. L. Liu, and F. Cuthbertson Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis Case Rep Med 2012 2012 134636
115. B. Singer, A.P. Ross, and K. Tobias Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis Int J Clin Pract 65 2011 887 895
116. J.M. Gelfand, R. Nolan, and D.M. Schwartz Microcystic macular oedema in multiple sclerosis is associated with disease severity Brain 135 2012 1786 1793
117. V. Martinelli, M. Gironi, and M. Rodegher Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment Ital J Neurol Sci 19 1998 65 67
118. D. Miller, F. Barkhof, and X. Montalban Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis Lancet Neurol 4 2005 281 288
119. C.H. Polman, S.C. Reingold, and G. Edan Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 2005 840 846
120. D.H. Miller, D.T. Chard, and O. Ciccarelli Clinically isolated syndromes Lancet Neurol 11 2012 157 169
121. D.S. Goodin, and D. Bates Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode Mult Scler 15 2009 1175 1182
122. J. Sellner, L. Schirmer, and B. Hemmer The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol 257 2010 1602 1611